Abstract:Objective: Hemangiomas are the most common benign vascular tumors of infancy. Although most infantile hemangiomas (IHs) have the ability to involute spontaneously after initial proliferation and resolve without consequence, intervention is required in a subset of IHs, which develop complications resulting in ulceration, bleeding, or aesthetic deformity. The primary treatment for this subset of IHs is pharmacological intervention, and propranolol has become the new first-line treatment for complicated hemangiomas. Here, we evaluated the efficacy of propranolol on proliferation IH in a clinical cohort including 578 patients.Methods: We retrospectively reviewed a total of 578 IH patients who were treated with oral propranolol from January 2010 to December 2012. Responses to the propranolol treatment were graded as: excellent, good, poor, or no response. Based on the response to propranolol treatment (once daily at a dose of 1.0 mg/kg for patients younger than 2 months; twice daily at daily total dose of 2 mg/kg for patients older than 2 months), additional pharmacotherapies or surgery were used for IH patients for satisfactory clinical outcome.Results: Five hundred and sixty (96.9%) of 578 IH patients in our study responded to oral propranolol treatment, and the response rate was significantly different for different ages of patients (P<0.05), with the youngest patients having the highest response rate. The mean time of treatment was 6 months (range, 3-12 months). For example, response rate to propranolol was 98.1% in patients younger than 2 months, compared with 93.3% in patients older than 2 months and younger than 8 months, and 73.7% in patients older than 8 months. One hundred and thirty one patients who exhibited incompletely involuted hemangiomas were further treated with timolol maleate (n=89) or pulsed dye laser (n=42). One hundred and seventeen (89.3%) of 131 patients showed a positive response. There were no instances of life-threatening complications after propranolol. However, minor side effects were observed including 10 (1.73%) cases of sleep disturbance, 7 (1.21%) cases of diarrhea, and 5 (0.86%) cases of bronchospasm.Conclusion: IH requires early intervention. During the involution phase, tapering propranolol dosage can be done to minimize side effects before discontinuing treatment. For patients exhibiting telangiectasia and chromatosis after propranolol treatment, administration of a 0.5% solution of timolol maleate or pulse dye laser is an effective therapeutic approach for complete involution.

Circulating Mesenchymal Stromal Cells in Patients with Infantile Hemangioma: Evaluation of Their Functional Capacity and Gene Expression Profile

CD133 Selected Stem Cells from Proliferating Infantile Hemangioma and Establishment of an in Vivo Mice Model of Hemangioma

Differentiation and Pro-Angiogenic Potential of Infantile Hemangioma Stem Cells

Propranolol for the treatment of infantile hemangiomas: a nine-year monocentric experience from a tertiary hospital

CD146+ mural cells from infantile hemangioma display proangiogenic ability and adipogenesis potential in vitro and in xenograft models

Three-Dimensional Microtumor Formation of Infantile Hemangioma-Derived Endothelial Cells for Mechanistic Exploration and Drug Screening

An endothelial SOX18-mevalonate pathway axis enables repurposing of statins for infantile hemangioma

Propranolol Inhibits Angiogenesis Via Down-Regulating the Expression of Vascular Endothelial Growth Factor in Hemangioma Derived Stem Cell

R(+) Propranolol decreases lipid accumulation in hemangioma-derived stem cells

[Effects of Propranolol on Proliferation of Hemangioma-Derived Mesenchymal Stem Cells ].

Efficacy and adverse effects of oral propranolol in infantile hemangioma: a meta-analysis of comparative studies

Ultrasonography as an objective tool for assessment of infantile hemangioma treatment with propranolol

Propranolol Therapy for Infantile Hemangioma: Our Experience

Propranolol Induces Regression of Hemangioma Cells Via the Down-Regulation of the Pi3k/Akt/Enos/Vegf Pathway

Efficacy of propranolol for cutaneous hemangiomas in premature children

Propranolol Reduces the Development of Lesions and Rescues Barrier Function in Cerebral Cavernous Malformations: A Preclinical Study.

Propranolol for infantile hepatic hemangioendothelioma: Clinical evaluation of drug efficacy and safety using a single-center patient cohort

MiR-187-3p Enhances Propranolol Sensitivity of Hemangioma Stem Cells

Serum-Level Changes of Vascular Endothelial Growth Factor in Children with Infantile Hemangioma after Oral Propranolol Therapy

Use of modified human hemangioma tissue cultures and human umbilical vein endothelial cell cultures to gain mechanistic insights into imiquimod treatment for infantile hemangioma

Apelin Receptor Can Act As a Specific Marker and Promising Therapeutic Target for Infantile Hemangioma